CN1438237A - Echinocystic acid preparation, medicinal preparation and new use as medicine - Google Patents
Echinocystic acid preparation, medicinal preparation and new use as medicine Download PDFInfo
- Publication number
- CN1438237A CN1438237A CN 03100676 CN03100676A CN1438237A CN 1438237 A CN1438237 A CN 1438237A CN 03100676 CN03100676 CN 03100676 CN 03100676 A CN03100676 A CN 03100676A CN 1438237 A CN1438237 A CN 1438237A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- filter
- echinocystic acid
- acid
- filtrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YKOPWPOFWMYZJZ-FMMUPTMQSA-N Echinocystic acid Natural products C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)C[C@H](O)[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C YKOPWPOFWMYZJZ-FMMUPTMQSA-N 0.000 title claims abstract description 72
- YKOPWPOFWMYZJZ-UHFFFAOYSA-N Echinocystsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C YKOPWPOFWMYZJZ-UHFFFAOYSA-N 0.000 title claims abstract description 72
- MCHWKJRTMPIHRA-UHFFFAOYSA-N n-(pyrrolidin-2-ylmethyl)aniline Chemical compound C1CCNC1CNC1=CC=CC=C1 MCHWKJRTMPIHRA-UHFFFAOYSA-N 0.000 title claims abstract description 72
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 132
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 17
- 210000004351 coronary vessel Anatomy 0.000 claims abstract description 11
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 10
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 8
- 238000000746 purification Methods 0.000 claims abstract description 5
- 239000011347 resin Substances 0.000 claims abstract description 5
- 229920005989 resin Polymers 0.000 claims abstract description 5
- 235000019441 ethanol Nutrition 0.000 claims description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 28
- 241000931143 Gleditsia sinensis Species 0.000 claims description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 24
- 239000000706 filtrate Substances 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 24
- 230000006837 decompression Effects 0.000 claims description 16
- 239000008367 deionised water Substances 0.000 claims description 16
- 229910021641 deionized water Inorganic materials 0.000 claims description 16
- 239000012065 filter cake Substances 0.000 claims description 16
- 238000010992 reflux Methods 0.000 claims description 16
- 208000031225 myocardial ischemia Diseases 0.000 claims description 15
- 230000007062 hydrolysis Effects 0.000 claims description 12
- 238000006460 hydrolysis reaction Methods 0.000 claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 12
- 229930182490 saponin Natural products 0.000 claims description 12
- 150000007949 saponins Chemical class 0.000 claims description 12
- 235000017709 saponins Nutrition 0.000 claims description 12
- 239000013078 crystal Substances 0.000 claims description 10
- 239000012043 crude product Substances 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 239000006187 pill Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 238000001953 recrystallisation Methods 0.000 claims description 8
- 238000004064 recycling Methods 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 239000003463 adsorbent Substances 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 4
- 239000000920 calcium hydroxide Substances 0.000 claims description 4
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 4
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000292 calcium oxide Substances 0.000 claims description 4
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 210000004165 myocardium Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000000284 extract Substances 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- 229930182478 glucoside Natural products 0.000 abstract 1
- 150000008131 glucosides Chemical class 0.000 abstract 1
- 239000012264 purified product Substances 0.000 abstract 1
- 239000000344 soap Substances 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000008899 fufang danshen Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002183 duodenal effect Effects 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 210000003516 pericardium Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ZGZLYKUHYXFIIO-UHFFFAOYSA-N 5-nitro-2h-tetrazole Chemical compound [O-][N+](=O)C=1N=NNN=1 ZGZLYKUHYXFIIO-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000533849 Gleditsia Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000009524 danshen dripping Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a new method of extracting industrially echinocystic acid from gleditshia and its new use. Return and extract Chinese traditional medicine, gleditshia, by 70-95% alcohol, purify to get total soap glucoside by the method of adjusting pH or D101 macroporous resin column layer separation, and then add acid with a certain concentration and bulk to make hydrolyzation and purification so as to get the purified product. It can be used as original material of Chinese medicinal preparation, has function of expanding coronary artery and can be used to prevent and cure coronary heart disease, angina and lack of blood of cardiac muscle.
Description
Technical field
The invention relates to the invention of extraction novel preparation method, pharmaceutical preparation and the new purposes thereof of Echinocystic acid (Echinocystic Acid), its new purposes is a coronary artery dilator, and prevention and treatment stenocardia, myocardial ischemia belong to the field of Chinese medicines.
Background technology
Chinese honey locust (Gleditsia Sinesis Lam.) has sensible, phlegm-dispelling functions, can be used for treatment of diseases such as apoplexy, belongs to the class Chinese medicine of having one's ideas straightened out.Contain abundant triterpenoid saponin in the Chinese honey locust, after acid hydrolysis, can obtain the triterpenic acid compounds, and have reducing blood-fat and suppress the cholesterol absorption effect.Echinocystic acid (Echinocystic Acid) has the free type of part to exist in Chinese honey locust, most of form with glycosides exists, before finishing, the present invention do not extract the preparation method about the Echinocystic acid industrialization, Echinocystic acid monomer also of no use is that raw material is made the pharmaceutical dosage form that allows on the pharmaceutics, and be used for the report of aspects such as prevention and treatment of diseases such as coronary heart disease and cerebral thrombosis, the launch relevant not more with the present invention.In Echinocystic acid separation and purification process in the past, be mostly with the research structure to be purpose, generally all use inflammable and explosive ether, Petroleum ether extraction, and then prepare the Echinocystic acid monomer with silica gel column chromatography separating purification.These methods only limit to research structure in the laboratory, and the production cycle is longer, and cost is also higher, and environment is also caused severe contamination.With Echinocystic acid is that raw material development dripping pill, tablet, capsule etc. are used for diseases such as coronary heart disease, stenocardia, cerebral thrombosis and did not appear in the newspapers before the present invention finishes.
The structure of Echinocystic acid (Echinocystic Acid):
Summary of the invention
One of purpose of the present invention has provided the pharmaceutical preparation of Echinocystic acid.
Two of purpose of the present invention has provided a kind of method for preparing Echinocystic acid.
Three of purpose of the present invention has provided Echinocystic acid and pharmaceutical preparation prevention thereof and has treated the new purposes of coronary heart disease, stenocardia, myocardial ischemia disease.
Pharmaceutical preparation of the present invention contains the Echinocystic acid of 1%-99% and the vehicle of 99%-1% (medicine that comprises other adapted); Preferably contain the Echinocystic acid of 30%-80% and the pharmaceutical excipient of 70%-20% (medicine that comprises other adapted); Preferably contain the Echinocystic acid of 60%-70% and the vehicle of 40%-30%.
Press practice of pharmacy, Echinocystic acid of the present invention can be prepared into the various clinical pharmaceutical dosage form, comprise the formulation of oral preparations or parenterai administration as preventing and treating coronary heart disease, stenocardia, myocardial ischemia disease.Said oral preparations is selected from any in tablet, capsule, pill, granule, suspensoid, dripping pill, the oral liquid; Said non-enteron aisle is selected from a kind of in the middle of injection, aerosol, suppository or the subcutaneous administration formulation to formulation.
The auxiliary material that the present invention is used for preventing and treat coronary heart disease, stenocardia, myocardial ischemia disease medicine is meant conventional vehicle, as solvent, disintegrating agent, correctives, sanitas, tinting material, tackiness agent etc.The present invention is used for preventing and treat the medicine that other compatibility of coronary heart disease, stenocardia, myocardial ischemia disease medicine is used, and the Echinocystic acid that refers to effective dose is certain medicine material, again compatibility other allowed the Chinese medicine or the pharmaceutical chemicals that share.
The preparation method of Echinocystic acid can be selected from a kind of in the following method:
1, gets dry Chinese honey locust (fruit) medicinal material, be cut into pieces, use twice of 60-90% alcohol reflux.Filter, merge extracted twice liquid, transferring pH value with calcium oxide or calcium hydroxide breast is 8-10, and abundant the stirring filtered, and it is 6-7 that filtrate is transferred PH with sulfuric acid, adds medicinal activated carbon purification again, filters decompression filtrate recycling ethanol, the dry Chinese honey locust total saponins that gets of concentrated solution.Get the Chinese honey locust total saponins, with ethanol liquid hydrolysis in 100 ℃ of water-baths of hydrochloric acid.Filter, discard hydrolyzed solution, filter cake is washed till neutrality with deionized water, gets the Echinocystic acid crude product; Use dissolve with ethanol again, it is an amount of to add medicinal gac, and heating in water bath refluxes, filtered while hot, filtrate decompression concentrates, and it is 5-6 that concentrated solution is transferred PH with dilute hydrochloric acid, placed 3-4 hour, and filtered, it is 3-4 that filtrate is transferred PH, placed 24 hours, filter, filter cake is washed till neutrality with deionized water, drying, use 95% ethyl alcohol recrystallization, get the Echinocystic acid white, needle-shaped crystals.
2, get dry Chinese honey locust (fruit) medicinal material, be cut into pieces, use twice of 60-90% alcohol reflux, filter, merge extracted twice liquid, add that medicinal gac fully stirs, filtration, concentrating under reduced pressure reclaim ethanol, concentrated solution is purifying on the D101 macroporous adsorbent resin of anticipating, wash with water to effluent liquid colourless earlier, use ethanol elution again, collect elutriant, decompression recycling ethanol, the dry Chinese honey locust total saponins that gets of concentrated solution.Get the Chinese honey locust total saponins, with ethanol liquid hydrolysis in 100 ℃ of water-baths of hydrochloric acid, filter, discard hydrolyzed solution, filter cake is washed till neutrality with deionized water, gets the Echinocystic acid crude product; Use ethanol (in the Echinocystic acid crude product) dissolving again, it is an amount of to add medicinal gac, and heating in water bath refluxes, filtered while hot, filtrate decompression concentrates, and it is 5-6 that concentrated solution is transferred PH with dilute hydrochloric acid, placed 3-4 hour, and filtered, it is 3-4 that filtrate is transferred PH, placed 24 hours, filter, filter cake is washed till neutrality with deionized water, drying, use 95% ethyl alcohol recrystallization, get the Echinocystic acid white, needle-shaped crystals.
Production technique of the present invention is with short production cycle, safety, and cost is low, the yield height, purity can reach more than 95%.Be particularly suitable for the industrialization mass production.The effect of the coronary artery dilator that has in view of Echinocystic acid, technology of the present invention industrialization from Chinese honey locust prepares Echinocystic acid in a large number and will hold out broad prospects.
The Echinocystic acid crystallinity monomer that aforesaid method of the present invention extracts, by high performance liquid chromatography and LC-MS stratographic analysis and in conjunction with the data analyses such as nucleus magnetic resonance that Chinese Academy of Sciences's Changchun applied chemistry research generation surveys, verify that the crystallinity monomer of method preparation of the present invention is exactly an Echinocystic acid.
Echinocystic acid that the present invention makes and pharmaceutical preparation thereof have coronary artery dilator, prevention and diseases such as treatment stenocardia, myocardial ischemia.These pharmacological actions can be confirmed by the pharmacodynamics test example.
Experimental example 1The checking of Echinocystic acid crystallinity monomer
1, high performance liquid phase (HPLC) is analyzed
Instrument: U.S. Agillent1100 type high performance liquid chromatograph (joining quaternary pump, diode array detector, automatic sampler, column oven, software is the multiple several automated processing systems of Agillent1100 type).
Condition: chromatographic column is Zorbax C
18Reverse phase silica gel post (4.6cmX150cm), sample size are 5ul, and moving phase is methyl alcohol: water (PH=3.7)=85: 15, flow velocity are 1.0ml/min, and the detection wavelength is 215nm.
Analytical results: the Echinocystic acid retention time is 4.385min.
2, liquid-matter coupling (LC/MSD) is analyzed
Instrument: U.S. Agillent liquid-matter combined instrument (joining quaternary pump, compensating unit pump, diode array detector, automatic sampler, column oven, software is Agillent1100 type several data treatment system).
Condition: chromatographic column is ZOBAX EXTEND C
18Post, moving phase are acetonitrile: water (PH is 3.5)=80: 20.Flow velocity is 0.9ml/min, and the post post-compensation is urged ionization reagent ammonia soln (0.1ml/min), and the mass spectrum condition is negative ion mode (NEG) electron spray(ES) (API-ESI) scanning.
Experimental example 2,Echinocystic acid is to the influence of anesthetized dog hat blood flow volume
Materials and methods
The adult assorted dog of animal health, female, male dual-purpose, body weight 12～18kg.
The medicine Echinocystic acid, Tianyao Science and Technology Co Ltd, Jilin Chemistry for Chinese Traditional Medicine chamber provides, white, needle-shaped crystals, lot number is 20020903; FUFANG DANSHEN DIWAN, specification: the 25mg/ grain, lot number: 20020414, Tianjin Tasly Pharmaceutical Co., Ltd's product; Vetanarcol, specification: the 25g/ bottle, lot number: 950427, Tong County, Beijing Fine Chemical Works product of cultivating people of ability.
Instrument CBI-8000 doppler blood flow instrument (U.S. BIOPAC company product); Powerlab/8s type eight derivatives are registering instrument and related accessories (Australian Ai De company product) according to one's analysis; SC-3 type breathing apparatus, Shanghai Medical Equipment Factory's product; HL-2 type constant flow pump, Shanghai City Hu Xi instrument plant product.
The method laboratory animal is divided into control group at random, and positive controls (nifedipine, 1.5mg/kg), totally 4 groups of Echinocystic acid high dosage (150mg/kg) and Echinocystic acid low dosages (50mg/kg).Laboratory animal intravenous injection 3% vetanarcol (30mg/kg) anesthesia.Operation on neck, trachea cannula connects the breathing apparatus, separates left carotid, and intubate writes down arteriotony through pressure transducer; Separate femoral vein for liquid make-up or anaesthetic; Duodenal intubation is done in abdominal operation, for duodenal administration; Open chest, vertically cut off pericardium, do the fixing heart that holds up of pocket, separate LCA, place the probe that is fit to bore, be used to measure coronary flow.Operation finishes, stablize 30min, earlier coronary artery blood flow contrasts before as administration under one section normal circumstances of record, begin administration then, positive control drug FUFANG DANSHEN DIWAN (Compound Danshen Dripping Pills, CDDP) and Echinocystic acid through duodenal administration, control animals gives equal-volume distilled water through duodenum, writes down 30min, 45min after the administration, 60min, 90min, 120min, 150min and 180min coronary artery blood flow (CAF) respectively.Different time has or not considerable change after more every observation index administration.Experimental data is added and subtracted standard deviation (x ± s) expression, t-check between statistical procedures method employing group with mean.
The result
After duodenum gave Echinocystic acid 150min, coronary artery blood flow obviously increased (P＜0.05) before than administration to experimental dog with 150mg/kg; To administration during 180min, the effect of its coronary blood flow increasing is obviously (P＜0.05) still, shows that Echinocystic acid has the effect of coronary blood flow increasing, sees Table 1.
Table 1. Echinocystic acid is to the influence of anesthetized dog coronary artery blood flow (x ± s)
After the administration of dosage example number before the administration of different time coronary flow (ml/min) group
Mg/kg (only) 30min 45min 60min 90min 120min 150min 180min contrast--5 32.7 ± 2.8 33.2 ± 3.3 34.5 ± 3.7 33.0 ± 1.2 35.5 ± 7.1 34.0 ± 6.6 31.4 ± 2.8 30.4 ± 2.5CDDP 300 5 28.8 ± 9.9 29.5 ± 10.4 31.3 ± 12.1 33.1 ± 13.2 30.8 ± 7.1 29.3 ± 9.6 28.9 ± 7.8 27.5 ± 7.3CDDP 150 5 30.8 ± 5.6 31.4 ± 11.1 30.8 ± 10.5 31.9 ± 10.8 29.9 ± 10.7 28.6 ± 11.6 30.4 ± 9.7 30.1 ± 9.6 echinocystic acid 150 5 26.9 ± 4.5 27.8 ± 4.4 28.2 ± 14.2 29.1 ± 5.1 30.7 ± 4.2 32.5 ± 4.8 35.9 ± 6.4*, 34.9 ± 3.9* echinocystic acid 50 5 28.7 ± 4.5 28.6 ± 5.1 29.2 ± 6.1 30.2 ± 6.6 30.21 ± 7.2 33.1 ± 10.8 32.9 ± 10.6 31.3 ± 8.7
Annotate: with before the administration relatively: * P＜0.05, all the other are P＞0.05
Experimental example 3,Echinocystic acid is to the influence of anesthetized dog myocardial ischemia effect
The animal health mongrel dogs, the male and female dual-purpose, body weight is 12.5-17.5kg.
The medicine Echinocystic acid, Tianyao Science and Technology Co Ltd, Jilin Chemistry for Chinese Traditional Medicine chamber provides, white, needle-shaped crystals, lot number is 20020903; FUFANG DANSHEN DIWAN, specification: the 25mg/ grain, lot number: 20020414, Tianjin Tasly Pharmaceutical Co., Ltd's product; Vetanarcol, specification: the 25g/ bottle, lot number: 950427, Tong County, Beijing Fine Chemical Works product of cultivating people of ability.
Method experiment divides four groups, each 5 of every group of domesticated dogs, and first group is physiology saline control group, second group of positive medicine FUFANG DANSHEN DIWAN (20mg/kg) group, third and fourth group is for being subjected to little, heavy dose of organize (10mg/kg, the 20mg/kg) of reagent.With domesticated dog with 3% vetanarcol (30mg/kg) intravenous anesthesia, separate tracheae, intubate connects breathing apparatus's (WH-2 type, Tianjin Medical Appliance Factory produces), the 4th intercostal is opened chest in the left side, expose heart, cut off pericardium, do the pericardium art and separate left anterior descending coronary artery, the stage casing threading is in order to ligation.Press infarct, marginarium, 24 epicardial leads of normal district's placement.Stablize 10min after operation is finished, measure normal epicardial electrogram then.Femoral venous catheter is got blood to measure AST, CK, LDH, does operation on duodenum and tests medicine and physiological saline, after administration 5,10,30,45,60,90,120,150,180,210,240,300,360min.The record epicardial electrogram, raising greater than 2mv with the S-T section is judging criterion, (S-T section total mv that raises is a ∑-ST), raises greater than the shared ratio of 2mv with the S-T section and calculates myocardial ischemia scope (N-ST) with this calculating myocardium degree of ischemia.Write down after 360 minutes, get blood for the second time, with AST, CK, LDH behind the mensuration medicine from femoral vein.Experiment is taken off heart after finishing, behind the normal saline flushing heart, the heavy whole-heartedly and left ventricular mass of weighing, be cut into 6 with left chamber is cross-section equably, place in nitro tetrazole orchid (N-BT) dye liquor, normal temperature dyeing 15min, measure the infarct (N-BT dye district) of every myocardium bilateral and non-infarct (N-BT dye district) outward with weighting method, every cardiac muscle is weighed, and calculates the weight of every cardiac muscle and the gross weight of infarct, calculates infarct and accounts for the left ventricle and the per-cent of dirty weight whole-heartedly.Get near fritter cardiac muscle (the coronary ligation line) and do pathological section, further observe the effect of medicine myocardial ischemia.The experimental result statistics is judged its significance with measured value t check.
The result
2.1 to the degree of myocardial ischemia (influence of ∑-ST)
The physiological saline control group does not have obvious effect to Σ-ST after administration.Positive drug control group had obvious statistical significance (P＜0.01) in 60-240 minute after administration.Small dose group had obvious statistical significance (P＜0.05) in 60-120 minute after administration.Heavy dose of group after administration 45-240 minute has obvious statistical significance (P＜0.01).The results are shown in Table 2.
2.2 influence to myocardial ischemia scope (N-ST)
The physiological saline group does not have obvious effect to N-ST after administration, positive drug control group after administration 60-240 minute has tangible statistical significance (P＜0.05).Small dose group after administration 60-210 minute has statistical significance (P＜0.05).Heavy dose of group after administration 60-240 minute has tangible statistical significance (P＜0.01).See Table 3.
Table 2 echinocystic acid is to dog acute myocardial ischemia degree, (the impact of ∑-ST), value 5 10 30 45 60 salt solution groups behind the value medicine before (x ± SD n=5) group dosage medicine, positive group 20mg/kg 5.76 ± 2.587 109.74 ± 19.647 128.16 ± 20.152 143.15 ± 20.470 128.75 ± 18.276 110.38 ± 12.753, (-) 5.75 ± 0.835 139.35 ± 29.185 146.74 ± 16.935 155.15 ± 18.012 147.75 ± 12.658 139.38 ± 21.275*Administration group 10mg/kg 5.74 ± 1.094 123.93 ± 22.567 134.76 ± 18.76 146.14 ± 20.189 130.55 ± 17.538 111.54 ± 10.555
*Administration group 20mg/kg 4.57 ± 1.139 126.93 ± 16.700 138.03 ± 13.429 148.04 ± 5.288 132.15 ± 4.917
*116.05 ± 4.634
*
90 120 150 180 210 240 300 360min142.38 ± 15.318 137.18 ± 24.313 142.62 ± 20.143 142.03 ± 20.337 125.18 ± 15.119 117.49 ± 14.989 104.37 ± 13.313 99.42 ± 15.437101.37 ± 9.859
*95.38 ± 8.206
*91.43 ± 6.538
* *92.00 ± 4.628
* *90.78 ± 3.954
*96.05 ± 6.010
*98.25 ± 2.773 100.83 ± 4.147102.25 ± 12.599
*91.76 ± 13.533
*102.43 ± 5.417
*109.80 ± 14.700
*103.17 ± 15.044
*102.38 ± 14.361 101.81 ± 16.083 102.41 ± 18.889104.07 ± 8.487
*86.75 ± 3.113
*88.02 ± 4.893
* *83.60 ± 4.975
* *93.05 ± 4.581
*94.84 ± 9.312
*101.80 ± 9.497 105.23 ± 7.950 with the salt solution group relatively:* P＜0.05; * P＜0.01 is worth positive group 20mg/kg 4.62 ± 1.674 15.43 ± 1.949 17.20 ± 16.43 17.20 ± 2.588 15.40 ± 1.817 13.22 ± 1.633,5 10 30 45 60 salt solution groups (-) 4.38 ± 1.816 18.01 ± 1.871 19.00 ± 1.000 18.00 ± 1.871 17.80 ± 2.864 18.03 ± 2.540 behind the front value of impact (x ± SD n=5) the group dosage medicine medicine of * * * P＜0.001 table 3 echinocystic acid to dog acute myocardial ischemia scope (N-ST)*Administration group 10mg/kg 3.41 ± 1.512 15.08 ± 2.236 18.40 ± 0.894 19.20 ± 1.304 16.60 ± 0.894 14.45 ± 1.170
*Administration group 20mg/kg 3.82 ± 1.303 17.05 ± 2.000 18.60 ± 0.894 17.80 ± 1.483 16.00 ± 1.225 13.62 ± 0.538
*
90 120 150 180 210 240 300 360min17.67±3.347 18.22±3.565 18.86±3.273 17.83±3.563 17.05±3.206 16.24±2.683 15.01±2.735 14.06±3.08611.20±1.654
** 12.64±0.546
**?11.45±1.676
** 10.82±1.644 11.46±2.194
* 11.83±1.643
*?12.05±1.583 11.42±1.14512.20±1.095
** 11.43±1.516
**?12.43±1.815
** 12.43±1.515
*?12.63±1.142
* 13.82±0.833 12.62±1.141 13.05±1.87312.40±0.548
** 12.02±1.224
**?12.02±1.416
** 11.05±0.703
**?11.44±0.544
**?11.22±0.81
** 12.24±0.835 11.87±0.832
Compare with the salt solution group: * P＜0.05, * * P＜0.01, * * * P＜0.001
Embodiment
Embodiment 1
Get dry Chinese honey locust (fruit) medicinal material 1kg, be cut into pieces (about 1cm is long), alcohol reflux twice, the twice ethanol consumption with 80% is respectively 7 times of amounts and 5 times of amounts of medicinal material weight, and the time is 3 hours.Filter, merge extracted twice liquid, transferring pH value with calcium oxide or calcium hydroxide breast is 9, fully stirs 2 hours, filter, it is 6 that filtrate is transferred PH with sulfuric acid, adds medicinal gac 30g purifying again, filters, decompression filtrate recycling ethanol ethanol, the dry about 150g of Chinese honey locust total saponins that gets of concentrated solution, with ethanol liquid (alcohol concn the is 45%) hydrolysis in water-bath (100 ℃) of 2000ml 2mol/L hydrochloric acid, hydrolysis time is 3 hours.Filter, discard hydrolyzed solution, filter cake is washed till neutrality with deionized water, and drying gets the about 42g of Echinocystic acid crude product; Use the 600ml dissolve with ethanol again, it is an amount of to add medicinal gac, and heating in water bath refluxes, filtered while hot, filtrate decompression concentrates, and it is 5-6 that concentrated solution is transferred PH with dilute hydrochloric acid, placed 3 hours, and filtered, it is 3-4 that filtrate is transferred PH, placed 24 hours, and filtered, filter cake is washed till neutrality with deionized water, dry, use 95% ethyl alcohol recrystallization, get the about 18g of Echinocystic acid white, needle-shaped crystals, yield is 1.8%.
Embodiment 2
Get dry Chinese honey locust (fruit) medicinal material 1kg, be cut into pieces (about 1cm is long), alcohol reflux twice, the twice ethanol consumption with 85% is 7 times of amounts of medicinal material weight, and the time is 3 hours.Filter, merge extracted twice liquid, add that medicinal gac 50g fully stirs, filtration, concentrating under reduced pressure reclaim ethanol to there not being the alcohol flavor, concentrated solution is purifying on the D101 macroporous adsorbent resin of anticipating, and washes with water to effluent liquid colourless earlier, use 85% ethanol elution again, collect elutriant, decompression recycling ethanol, the dry about 140g of Chinese honey locust total saponins that gets of concentrated solution, with ethanol liquid (alcohol concn the is 45%) hydrolysis in water-bath (100 ℃) of 1800ml 2mol/L hydrochloric acid, hydrolysis time is 3 hours.Filter, discard hydrolyzed solution, filter cake is washed till neutrality with deionized water, gets the about 40g of Echinocystic acid crude product; Use the 600ml dissolve with ethanol again, it is an amount of to add medicinal gac, and heating in water bath refluxes, filtered while hot, filtrate decompression concentrates, and it is 5-6 that concentrated solution is transferred PH with dilute hydrochloric acid, placed 3-4 hour, and filtered, it is 3-4 that filtrate is transferred PH, placed 24 hours, and filtered, filter cake is washed till neutrality with deionized water, dry, use 95% ethyl alcohol recrystallization, get Echinocystic acid white, needle-shaped crystals 19g, yield is 1.9%.
Embodiment 3(capsule)
Echinocystic acid raw material 1000g, medical starch 1000g mixes, the capsule of packing into No. 1, every 0.2g, each oral 2-3 grain, twice of every day.
Embodiment 4(tablet)
Echinocystic acid raw material 1000g, medical starch 400g, dextrin 100g mixes, and uses an amount of alcohol granulation, through the whole grain of pelletizing machine, compressing tablet, every 0.25g, oral, each 2, twice of every day.
Embodiment 5(injection)
Echinocystic acid raw material 10g, propylene glycol 20ml, polyoxyethylene glycol-400 50ml, water for injection 300ml mixes heating in water bath 30 minutes, add phenylcarbinol 50ml, add to 1000ml with water for injection again, in ultrasonic wave, handled 10 minutes, heated 30 minutes in the water-bath again, transfer pH value 5.5-6.5, filter clear and bright, embedding, the sterilization promptly.Every 2ml, intramuscular injection, a 2ml, 1-2 time on the one.
Embodiment 6(pill)
Take by weighing the 300g Macrogol 4000, in water-bath, melt, add Echinocystic acid raw material 100g, stir, in the impouring insulating pipe, regulate thermostat, make soup under 80-90 ℃, splash in the whiteruss that cooled off (temperature ± 4 ℃), after dripping off, to blot paraffin oil on the pill impouring filter paper, add a small amount of talcum powder again, mixing gets 1000 of Echinocystic acid dripping pills.Oral, a 2-3 grain, three times on the one, one after each meal.
Claims (10)
1, a kind of pharmaceutical preparation is characterized in that containing Echinocystic acid and one or more pharmaceutically acceptable vehicle for the treatment of significant quantity.
2, pharmaceutical preparation according to claim 1, it is held to levy and is: contain the Echinocystic acid of 1%-99% and the vehicle of 99%-1%.
3, medicine according to claim 2 is characterized in that containing the Echinocystic acid of 60%-70% and the vehicle of 40%-30%.
4, pharmaceutical preparation according to claim 1 is characterized in that the activeconstituents that also can be used for other coronary artery dilators, prevention and diseases such as treatment stenocardia and myocardial ischemia makes up.
5, a kind of method for preparing Echinocystic acid is characterized in that this method is selected from a kind of in following two kinds of methods:
A, get dry Chinese honey locust (fruit) medicinal material, be cut into pieces, with twice of 60-90% alcohol reflux; Filter, merge extracted twice liquid, transferring pH value with calcium oxide or calcium hydroxide breast is 8-10, and abundant the stirring filtered, and it is 6-7 that filtrate is transferred PH with sulfuric acid, adds medicinal activated carbon purification again, filters decompression filtrate recycling ethanol, the dry Chinese honey locust total saponins that gets of concentrated solution; Get the Chinese honey locust total saponins, with ethanol liquid hydrolysis in 100 ℃ of water-baths of hydrochloric acid; Filter, discard hydrolyzed solution, filter cake is washed till neutrality with deionized water, gets the Echinocystic acid crude product; Use dissolve with ethanol again, it is an amount of to add medicinal gac, and heating in water bath refluxes, filtered while hot, filtrate decompression concentrates, and it is 5-6 that concentrated solution is transferred PH with dilute hydrochloric acid, placed 3-4 hour, and filtered, it is 3-4 that filtrate is transferred PH, placed 24 hours, filter, filter cake is washed till neutrality with deionized water, drying, use 95% ethyl alcohol recrystallization, get the Echinocystic acid white, needle-shaped crystals;
B, get dry Chinese honey locust (fruit) medicinal material, be cut into pieces, with twice of 60-90% alcohol reflux, filter, merge extracted twice liquid, add that medicinal gac fully stirs, filtration, concentrating under reduced pressure reclaim ethanol, concentrated solution is purifying on the D101 macroporous adsorbent resin of anticipating, wash with water to effluent liquid colourless earlier, use ethanol elution again, collect elutriant, decompression recycling ethanol, the dry Chinese honey locust total saponins that gets of concentrated solution; Get the Chinese honey locust total saponins, with ethanol liquid hydrolysis in 100 ℃ of water-baths of hydrochloric acid, filter, discard hydrolyzed solution, filter cake is washed till neutrality with deionized water, gets the Echinocystic acid crude product; Use dissolve with ethanol again, it is an amount of to add medicinal gac, and heating in water bath refluxes, filtered while hot, filtrate decompression concentrates, and it is 5-6 that concentrated solution is transferred PH with dilute hydrochloric acid, placed 3-4 hour, and filtered, it is 3-4 that filtrate is transferred PH, placed 24 hours, filter, filter cake is washed till neutrality with deionized water, drying, use 95% ethyl alcohol recrystallization, get the Echinocystic acid white, needle-shaped crystals.
6, the preparation method of Echinocystic acid as claimed in claim 5 is characterized in that this method is selected from a kind of in following two kinds of methods:
A. get dry Chinese honey locust (fruit) medicinal material 1 weight part, cutting is into about the long section of 1cm, and alcohol reflux twice, the twice ethanol consumption with 80% is respectively 7 times of amounts and 5 times of amounts of medicinal material weight, and the time is 3 hours; Filter, merge extracted twice liquid, transferring pH value with calcium oxide or calcium hydroxide breast is 9, fully stirs 2 hours, filter, it is 6 that filtrate is transferred PH with sulfuric acid, adds medicinal gac 0.03 weight part purifying again, filters, decompression filtrate recycling ethanol ethanol, concentrated solution dry the Chinese honey locust total saponins, be ethanol liquid hydrolysis in 100 ℃ of water-baths of 45% with the concentration of about 2 parts by volume 2mol/L hydrochloric acid, hydrolysis time is 3 hours; Filter, discard hydrolyzed solution, filter cake is washed till neutrality with deionized water, and drying gets the Echinocystic acid crude product approximately; Use about 0.6 parts by volume dissolve with ethanol again, it is an amount of to add medicinal gac, and heating in water bath refluxes, filtered while hot, filtrate decompression concentrates, and it is 5-6 that concentrated solution is transferred PH with dilute hydrochloric acid, placed 3 hours, and filtered, it is 3-4 that filtrate is transferred PH, placed 24 hours, filter, filter cake is washed till neutrality with deionized water, drying, use 95% ethyl alcohol recrystallization, get the Echinocystic acid white, needle-shaped crystals;
B. get dry Chinese honey locust (fruit) medicinal material 1 weight part, cutting is into about the long section of 1cm, and alcohol reflux twice, the twice ethanol consumption with 85% is 7 times of amounts of medicinal material weight, and the time is 3 hours; Filter, merge extracted twice liquid, add that medicinal gac 0.05 weight fully stirs, filtration, concentrating under reduced pressure reclaim ethanol to there not being the alcohol flavor, concentrated solution is purifying on the D101 macroporous adsorbent resin of anticipating, and washes with water to effluent liquid colourless earlier, use 85% ethanol elution again, collect elutriant, decompression recycling ethanol, concentrated solution is dry that the Chinese honey locust total saponins is about, with the concentration of about 1.8 parts by volume 2mol/L hydrochloric acid is ethanol liquid hydrolysis in 100 ℃ of water-baths of 45%, and hydrolysis time is 3 hours; Filter, discard hydrolyzed solution, filter cake is washed till neutrality with deionized water, gets the Echinocystic acid crude product; Use about 0.6 parts by volume dissolve with ethanol again, it is an amount of to add medicinal gac, and heating in water bath refluxes, filtered while hot, filtrate decompression concentrates, and it is 5-6 that concentrated solution is transferred PH with dilute hydrochloric acid, placed 3-4 hour, and filtered, it is 3-4 that filtrate is transferred PH, placed 24 hours, filter, filter cake is washed till neutrality with deionized water, drying, use 95% ethyl alcohol recrystallization, get the Echinocystic acid white, needle-shaped crystals.
7,, it is characterized in that said medicine is oral preparations or parenterai administration agent type according to the described pharmaceutical preparation of claim 1-4.
8, pharmaceutical preparation according to claim 7 is characterized in that said oral preparations is selected from a kind of in the middle of the tablet, pill, capsule, granule, suspensoid, dripping pill, oral liquid.
9, pharmaceutical preparation according to claim 7 is characterized in that said parenterai administration formulation is selected from a kind of in the middle of the injection, aerosol, suppository form of administration.
10, the application of Echinocystic acid in medicines such as coronary artery dilator, prevention and treatment coronary heart disease, stenocardia, myocardial ischemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03100676 CN1216896C (en) | 2003-01-21 | 2003-01-21 | Echinocystic acid preparation, medicinal preparation and new use as medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03100676 CN1216896C (en) | 2003-01-21 | 2003-01-21 | Echinocystic acid preparation, medicinal preparation and new use as medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1438237A true CN1438237A (en) | 2003-08-27 |
| CN1216896C CN1216896C (en) | 2005-08-31 |
Family
ID=27673807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03100676 Expired - Lifetime CN1216896C (en) | 2003-01-21 | 2003-01-21 | Echinocystic acid preparation, medicinal preparation and new use as medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1216896C (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010130152A1 (en) * | 2009-05-15 | 2010-11-18 | 成都康弘制药有限公司 | Pharmaceutical composition for treating cardiovascular disorder and use thereof |
| CN102240293A (en) * | 2010-05-11 | 2011-11-16 | 成都康弘制药有限公司 | Application of echinocystic acid in preparing medicament preventing and treating cardiovascular diseases |
| CN101919901B (en) * | 2009-06-10 | 2012-01-11 | 赵全成 | Application of total aglycone of Gleditsia sinensis Lam in preparation of alpha-glucosidase inhibitor drugs |
| CN102464698A (en) * | 2010-11-19 | 2012-05-23 | 苏州宝泽堂医药科技有限公司 | Method for preparing high-content echinocystic acid |
| CN103145790A (en) * | 2013-03-18 | 2013-06-12 | 山东省中医药研究院 | Method for simultaneously preparing oleanolic acid and echinocystic acid from fructus gleditsiae |
| WO2014063441A1 (en) * | 2012-10-22 | 2014-05-01 | 北京大学 | Triterpene derivative and its anti-influenza use |
| CN106550942A (en) * | 2016-10-17 | 2017-04-05 | 徐州得铸生物科技有限公司 | A kind of bactericidal composition containing 1,8 cineoles |
| CN110563792A (en) * | 2019-09-09 | 2019-12-13 | 南开大学 | G protein coupled bile acid receptor agonist and application thereof |
-
2003
- 2003-01-21 CN CN 03100676 patent/CN1216896C/en not_active Expired - Lifetime
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010130152A1 (en) * | 2009-05-15 | 2010-11-18 | 成都康弘制药有限公司 | Pharmaceutical composition for treating cardiovascular disorder and use thereof |
| JP2012526730A (en) * | 2009-05-15 | 2012-11-01 | 成都康弘制薬有限公司 | Pharmaceutical composition for the treatment of cardiovascular disorders and use thereof |
| CN101919901B (en) * | 2009-06-10 | 2012-01-11 | 赵全成 | Application of total aglycone of Gleditsia sinensis Lam in preparation of alpha-glucosidase inhibitor drugs |
| CN102240293A (en) * | 2010-05-11 | 2011-11-16 | 成都康弘制药有限公司 | Application of echinocystic acid in preparing medicament preventing and treating cardiovascular diseases |
| CN102240293B (en) * | 2010-05-11 | 2013-04-24 | 成都康弘制药有限公司 | Application of echinocystic acid in preparing medicament preventing and treating cardiovascular diseases |
| CN102464698A (en) * | 2010-11-19 | 2012-05-23 | 苏州宝泽堂医药科技有限公司 | Method for preparing high-content echinocystic acid |
| JP2015535222A (en) * | 2012-10-22 | 2015-12-10 | 北京大学 | Triterpene derivatives and their use for anti-influenza |
| WO2014063441A1 (en) * | 2012-10-22 | 2014-05-01 | 北京大学 | Triterpene derivative and its anti-influenza use |
| CN103768078A (en) * | 2012-10-22 | 2014-05-07 | 北京大学 | Triterpenoid derivatives and anti-influenza application thereof |
| EP2910563A4 (en) * | 2012-10-22 | 2016-05-25 | Univ Beijing | Triterpene derivative and its anti-influenza use |
| US9920088B2 (en) | 2012-10-22 | 2018-03-20 | University of Macao | Triterpene derivative and its anti-influenza use |
| CN103768078B (en) * | 2012-10-22 | 2019-02-05 | 北京大学 | Tetraterpene derivatives and its anti influenza purposes |
| CN103145790A (en) * | 2013-03-18 | 2013-06-12 | 山东省中医药研究院 | Method for simultaneously preparing oleanolic acid and echinocystic acid from fructus gleditsiae |
| CN106550942A (en) * | 2016-10-17 | 2017-04-05 | 徐州得铸生物科技有限公司 | A kind of bactericidal composition containing 1,8 cineoles |
| CN110563792A (en) * | 2019-09-09 | 2019-12-13 | 南开大学 | G protein coupled bile acid receptor agonist and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1216896C (en) | 2005-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1216896C (en) | Echinocystic acid preparation, medicinal preparation and new use as medicine | |
| CN1210289C (en) | Radde anemone rhizome extract and its prepn process and use | |
| CN104940216B (en) | The application of galloyl glucose glycoside derivative and the pharmaceutical composition for treating hyperuricemia | |
| CN101919901B (en) | Application of total aglycone of Gleditsia sinensis Lam in preparation of alpha-glucosidase inhibitor drugs | |
| CN101307090B (en) | Method for preparing timosaponin BIII and uses thereof | |
| JP3128823B2 (en) | Anticancer compound and method for producing the same | |
| CN101564405A (en) | Application of total aglycone of himalayan teasel roots and single-component hederagenin in medicaments preparing Alpha-glucosidase inhibitor | |
| CN101343299A (en) | Lxeris sonchifolia(bunge)hance flavone extract, preparation method and application thereof | |
| CN113861135B (en) | Radix aucklandiae tetrol and pharmaceutical composition thereof, and preparation method and application thereof | |
| CN1114413C (en) | Application of emodin-8-0-beta-D-glucoside | |
| CN1682746A (en) | Use of clasping gutweed flavonoid in preparing medicine for treating coronary heart disease | |
| CN100584345C (en) | Distillage of Ardisia chinensis Benth of possessing function of antivirus, extraction method and application | |
| CN1282468C (en) | Chinese medicine soft capsule Naodesheng and its preparing method | |
| CN1560061A (en) | Process for extracting dioscored soap oside from dioscorea | |
| CN1068790C (en) | Medicinal composition containing total saponin extracted from stem and leaves of American ginseng | |
| EP0014471B1 (en) | Acylated derivatives of a water extract of anemarrhenae rhizoma and hypoglycemic agents containing said derivatives | |
| CN1923191B (en) | Use of flavanone kind composition in preparation of medicine for curing cardio vascular diseases | |
| CN101633661B (en) | Process for preparing sodium cantharidinate | |
| CN101249129B (en) | Chinese medicine extract combination and medicine use thereof | |
| CN101375954B (en) | Medicament composition, preparation method thereof and use | |
| CN100355424C (en) | Extractive of 'Zong'wood for treating diabetes, and application of saponin of 'Zong' wood for treating diabetes | |
| CN112961203B (en) | Flavonol glycoside derivative and its use and preparation method | |
| CN115737698B (en) | Application of armored grass extract in inhibiting glucosidase | |
| CN112500444B (en) | Compound and preparation method and application thereof | |
| CN102070700A (en) | Marsdenia tenacissima saponins H and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: CHENGDU KANGHONG TECHNOLOGY INDUSTRIAL (GROUP) CO Free format text: FORMER OWNER: TIANYAO SCIENCE AND TECHNOLOGY CO LTD, JILIN Effective date: 20060317 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20060317 Address after: 610036 No. 36 Shu West Road, Chengdu, Sichuan, Jinniu District Patentee after: Chengdu Kanghong technology industry (Group) Co.,Ltd. Address before: 130103 No. 509 Mao Xiang street, hi tech Development Zone, Jilin, Changchun Patentee before: JILIN TIANYAO SCIENCE AND TECHNOLOGY Co.,Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHENGDU KANGHONG TECHNOLOGY INDUSTRIAL (GROUP) CO., LTD. Effective date: 20080912 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20080912 Address after: No 36, Shu West Road, Chengdu, Sichuan, Jinniu District Patentee after: Chengdu Kanghong Pharmaceutical Co.,Ltd. Address before: No 36, Shu West Road, Chengdu, Sichuan, Jinniu District Patentee before: Chengdu Kanghong technology industry (Group) Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20050831 |
|
| CX01 | Expiry of patent term |